Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...
June 03, 2026 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic OutcomesLate-Breaking...
June 03, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...
June 03, 2026 03:30 ET | Source: SNS Insider pvt ltd

Photomask Market Size to Grow USD 8.19 Billion by 2035 | Research by SNS Insider

Global Photomask Market Size, Share, Trends & Segment Analysis by Product, Application, Technology, End Use, Region & Forecast 2026-2035
June 01, 2026 08:00 ET | Source: Senseonics Holdings, Inc.

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of...
June 01, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with...
May 29, 2026 09:30 ET | Source: SNS Insider pvt ltd

Fleet Management Market to Reach USD 88.74 Billion by 2035 as EV Adoption and E-commerce Logistics Accelerate Worldwide | SNS Insider

Austin, May 29, 2026 (GLOBE NEWSWIRE) -- The Fleet Management Market is projected to increase at a compound annual growth rate (CAGR) of 13.48% from 2026 to 2035, from its 2025 valuation of USD...
May 28, 2026 03:30 ET | Source: ViCentra

ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics

ViCentra triples Kaleido manufacturing capacity via Phillips Medisize partnership, enabling patch pump supply for 17,000+ users across European markets.
May 27, 2026 09:05 ET | Source: MannKind

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS
May 27, 2026 03:00 ET | Source: Zealand Pharma

Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions

Press release – No. 10 / 2026 Zealand Pharma to Present Data atthe American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as...